Kerri Ilene Aronson, MD

Assistant Professor of Medicine

Pulmonary Medicine and Critical Care (Medicine)

Contact & profiles

Appointments

Past Appointments

Show all 4

Centers

Education

Highlights

1
American journal of respiratory and critical care medicine · 2021
KIKerri Ilene Aronson MMMonika M Safford
PMID: 34283696PMCID: PMC8650796DOIFirst author94 citations
2
American journal of respiratory and critical care medicine · 2023
KIKerri Ilene Aronson JKJamuna Krishnan APAnna Podolanczuk RJRobert J. Kaner+1 more →LPLaura Pinheiro
PMID: 37099412PMCID: PMC10395489DOIFirst author28 citations
3
Respiratory research · 2021
KIKerri Ilene Aronson MMMonika M Safford
PMID: 34376172PMCID: PMC8353836DOIFirst author16 citations

5 grants

PI
Dr. Kerri Aronson service agreement with PFF
Pulmonary Fibrosis Foundation · 2026–2027Contract
PFF 262377-01
PI
Rise-HP: Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis; A Stakeholder Engaged Intervention to Improve Health-Related Quality of Life
National Heart, Lung, and Blood Institute · 2022–2027· 2 renewals
K23HL163394-03S1
KP
Center to Improve Chronic disease Outcomes through Multi-level and Multi-generational approaches Unifying Novel Interventions and Training for health EquitY (Investigator Development Core)
National Institute on Minority Health and Health Disparities · 2021–2027 · via Columbia University
No publications yet
P50MD017341-05
PI
Development of a Stakeholder Engaged Intervention to Improve Knowledge and Health-Related Quality of Life in SSc-ILD
Scleroderma Foundation · 2022–2026
SF 221362-03
PI
Stakeholder Engaged Intervention Development of a Novel Digital Health Curriculum for Hypersensitivity Pneumonitis
American Lung Association, Incorporated · 2022–2025
ALA CA-943664

Completed grants (1)

PI
Development and Validation of a Disease Specific Health Related Quality of Life Instrument for Patients with Chronic Hypersensitivity Pneumonitis
Pulmonary Fibrosis Foundation · 2019–2021
PFF 193227-01

3 studies

PI
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Interstitial Lung Disease Prospective Outcomes (IPF-PRO/ILD-PRO) Registry
Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · OPEN TO ACCRUAL (as of 2025)
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
NCT01915511
PI
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
NA · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Hypersensitivity Pneumonitis
NCT06811389
PI
Reimagining Interventions for Support and Education in Interstitial Lung Disease
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)

Completed & closed trials (4)

PI
Stakeholder Engaged Intervention Development of a Patient Education Curriculum for Scleroderma-related Interstitial Lung Disease (SSc-ILD) Branyplus transfer
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
PI
Stakeholder Attitudes and Preferences for a Peer Support and Education Intervention for patients with Interstitial Lung Disease
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2024)
PI
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis (RISE-HP); Qualitative Study BRANY transfer
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
PI
Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)

Avalyn Pharma, Inc. · PureTech Health · Trevi Therapeutics

Pulmonary Fibrosis Foundation

Trevi Therapeutics